SALT LAKE CITY, March 26, 2019 /PRNewswire/ -- Lipocine Inc.
(NASDAQ: LPCN), a specialty pharmaceutical company, announced today
acceptance of their abstract for late-breaker presentation on LPCN
1144 clinical results as part of The International Liver Congress™
2019, the annual meeting of the European Association for the Study
of the Liver ("EASL"). The presentation will detail LPCN 1144
clinical results with respect to post-treatment changes in liver
fat assessed using magnetic resonance imaging, proton density
fat fraction ("MRI-PDFF") technique, as well as changes in key
serum biomarkers typically associated with non-alcoholic
steatohepatitis ("NASH"). The International Liver
Congress™ is being held April
10th – 14th in Vienna, Austria.
Presentation
Details
|
Title:
|
LPCN 1144, an
Androgen Receptor Agonist Targeted for NASH, Reduces Liver Fat and
Key Serum Biomarkers
|
Publication
Number:
|
5468
(LBP-03)
|
Date:
|
April 11,
2019
|
Location:
|
Reed Messe Wien
Congress and Exhibition Center, Vienna, Austria
|
Time:
|
9 a.m. CEST – 5 p.m.
CEST
|
"We look forward to sharing LPCN 1144 clinical results as part
of The International Liver Congress™ 2019," stated Mahesh Patel, Ph.D., Lipocine's Chairman,
President and Chief Executive Officer.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical company developing
innovative pharmaceutical products to treat metabolic and endocrine
disorders using its proprietary drug delivery technologies.
Lipocine's clinical development pipeline includes four development
programs TLANDO, LPCN 1144, LPCN 1111 and LPCN 1107. TLANDO, a
novel oral prodrug of testosterone containing testosterone
undecanoate, is designed to help restore normal testosterone levels
in hypogonadal men. LPCN 1144, an oral prodrug of bioidentical
testosterone, is being developed as a treatment of non-alcoholic
steatohepatitis ("NASH") and recently completed a proof-of-concept
clinical study demonstrating substantial liver fat reductions in
hypogonadal males assessed using magnetic resonance imaging,
proton density fat fraction ("MRI-PDFF")
technique. LPCN 1111, a novel oral prodrug
of testosterone, originated and is being developed by Lipocine as a
next-generation oral testosterone product with potential for
once-daily dosing and is currently in Phase 2 testing. LPCN 1107 is
potentially the first oral hydroxyprogesterone caproate product
candidate indicated for the prevention of recurrent preterm birth
and has been granted orphan drug designation by the FDA. An End of
Phase 2 meeting with the FDA has been completed. For more
information, please visit www.lipocine.com.
Forward-Looking Statements
This release contains "forward looking statements" that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 and include statements that are not
historical facts regarding Lipocine's product candidates and
related clinical trials and the FDA review process relating to its
product candidates, the path to approvability by the FDA of
Lipocine's development programs, the potential uses and benefits of
our product candidates, including LPCN 1144, and our product
development efforts. Investors are cautioned that all such
forward-looking statements involve risks and uncertainties,
including, without limitation, the risks that the FDA will not
approve any of our products, risks related to our products,
expected product benefits not being realized, clinical and
regulatory expectations and plans not being realized, new
regulatory developments and requirements, risks related to the FDA
approval process including the receipt of regulatory approvals, the
results and timing of clinical trials, patient acceptance of
Lipocine's products, the manufacturing and commercialization of
Lipocine's products, and other risks detailed in Lipocine's filings
with the SEC, including, without limitation, its Form 10-K and
other reports on Forms 8-K and 10-Q, all of which can be obtained
on the SEC website at www.sec.gov. Lipocine assumes no obligation
to update or revise publicly any forward-looking statements
contained in this release, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lipocine-late-breaker-presentation-at-easl-meeting-to-detail-lpcn-1144-mri-pdff-based-clinical-results-on-reduction-of-liver-fat-and-key-serum-biomarkers-300815937.html
SOURCE Lipocine Inc.